Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study.
Annemarie B van der Aart-van der BeekEllen ApperlooNiels JongsDennis B RouwC David SjöströmIris FriedliLars JohanssonDaniël H van RaalteKlaas HoogenbergHiddo J Lambers HeerspinkPublished in: Diabetes, obesity & metabolism (2023)
In participants with type 2 diabetes and albuminuria, treatment with dapagliflozin, exenatide and dapagliflozin-exenatide reduced albuminuria, with a numerically larger reduction in the combined dapagliflozin-exenatide treatment group.
Keyphrases